Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Gilead (GILD) to Showcase New Cancer Therapy Data

AI-generated analysis

📅 Gilead Sciences (NASDAQ: GILD) announced on May 21, 2026, that it will present over 25 abstracts at the 2026 ASCO Annual Meeting and EHA Congress.

🔬 Key presentations include new late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer focusing on long-term progression-free survival.

🧬 For the first time, Kite will introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma at these conferences.

🩺 EHA updates will showcase durability and safety results for KITE-753, an enhanced CAR T-cell therapy targeting relapsed/refractory B-cell lymphoma.

💊 Gilead also announced new Phase 3 interim data showing Livdelzi achieved high and sustained normalization of the liver marker ALP in primary biliary cholangitis patients.

⏳ The Livdelzi results indicate the drug was well-tolerated over a two-year treatment period for primary biliary cholangitis patients.

🏢 Gilead Sciences, founded in 1987 and headquartered in California, develops medicines for unmet medical needs including HIV-1, hepatitis C, and serious fungal infections.

💰 The company has paid uninterrupted quarterly dividends for ten consecutive years, highlighting its status as a reliable dividend stock.

📊 The article notes that Gilead is considered one of the 10 safest dividend stocks to buy right now according to the publication's analysis.

⚠️ The text includes an investment conviction statement suggesting some AI stocks may offer higher returns and greater upside potential than GILD.

🔗 Readers are directed to additional reports on Leopold Aschenbrenner’s portfolio and Steve Cohen’s stock picks for further investment ideas.

Bullish Signals
  • Gilead Sciences is recognized as one of the 10 Safest Dividend Stocks to Buy Right Now.
  • The company will present over 25 abstracts at major medical conferences, showcasing significant progress in cancer therapies.
  • New late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer are being presented, focusing on long-term progression-free survival.
  • Kite will introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma.
  • EHA updates will showcase the durability and safety of KITE-753, an enhanced CAR T-cell therapy targeting relapsed/refractory B-cell lymphoma.
  • New Phase 3 interim data shows Livdelzi achieved high and sustained normalization of a key liver marker (ALP) in primary biliary cholangitis patients.
  • Livdelzi was well-tolerated over two years of treatment, demonstrating strong safety and efficacy.
  • Gilead has paid uninterrupted quarterly dividends for ten consecutive years.
Risk Factors
  • The article explicitly states that while acknowledging Gilead's risk, the author believes some AI stocks hold greater promise for delivering higher returns within a shorter time frame.
  • The article suggests that if an investor is looking for an AI stock with more promising upside potential than GILD, they should check out a report about another 'cheapest AI stock' instead.
Full Analysis
Gilead Sciences (NASDAQ: GILD) is set to present over 25 abstracts at the 2026 ASCO Annual Meeting and EHA Congress, highlighting progress in its cancer therapy pipeline. Key presentations include late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer, focusing on long-term progression-free survival. Additionally, Kite will introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma, and showcase durability and safety results for KITE-753, an enhanced CAR T-cell therapy targeting relapsed/refractory B-cell lymphoma. Separately, Gilead announced new Phase 3 interim data for Livdelzi in primary biliary cholangitis patients, demonstrating high and sustained normalization of the key liver marker ALP over two years of treatment with good tolerability. The company, founded in 1987 and headquartered in California, develops medicines for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections, having paid uninterrupted quarterly dividends for ten consecutive years.